CAJ | 학술논문

目的使用国产120 W高功率绿激光手术系统治疗150例伴有下尿路梗阻的良性前列腺增生(BPH )患者 ,通过分析患者术前术后尿路指标来评估该高功率绿激光治疗BPH的安全性及有效性.方法 2013年2~12月对150例BPH进行PVP手术治疗 ,对手术时间、血清钠、出血量、光纤能量消耗、术后留置导尿管时间、最大尿流率(Qmax)、国际前列腺症状评分(IPSS)、生活质量指数(QOL)、残余尿(PVR)、并发症等指标进行评价.结果 136例单用绿激光顺利完成手术 ,14例辅以经尿道前列腺电切术(TURP)完成手术 ;平均手术时间(38 ± 20 .5)(30~80)min;术前、术后血清钠均值分别为(139 ± 1 .0)、(138 .5 ± 1 .9) mmol/L ;术后平均留置导尿管时间(40 ± 18 )(36~96 )h;术后平均最大尿流率由术前(6 .3 ± 3 .5 )m L/s提高到(18 .5 ± 5 .6 ) m L/s ;平均光纤能量消耗(216 ± 58)kJ.术后IPSS、QOL较术前均明显改善 ,均未出现电切综合征 ,无输血、死亡病例.结论国产120 W高功率绿激光治疗BPH时手术安全 ,并发症少 ,能达到满意的疗效.
목적 사용국산120 W고공솔록격광수술계통치료150례반유하뇨로경조적량성전렬선증생(BPH )환자 ,통과분석환자술전술후뇨로지표래평고해고공솔록격광치료BPH적안전성급유효성.방법 2013년2~12월대150례BPH진행PVP수술치료 ,대수술시간、혈청납、출혈량、광섬능량소모、술후류치도뇨관시간、최대뇨류솔(Qmax)、국제전렬선증상평분(IPSS)、생활질량지수(QOL)、잔여뇨(PVR)、병발증등지표진행평개.결과 136례단용록격광순리완성수술 ,14례보이경뇨도전렬선전절술(TURP)완성수술 ;평균수술시간(38 ± 20 .5)(30~80)min;술전、술후혈청납균치분별위(139 ± 1 .0)、(138 .5 ± 1 .9) mmol/L ;술후평균류치도뇨관시간(40 ± 18 )(36~96 )h;술후평균최대뇨류솔유술전(6 .3 ± 3 .5 )m L/s제고도(18 .5 ± 5 .6 ) m L/s ;평균광섬능량소모(216 ± 58)kJ.술후IPSS、QOL교술전균명현개선 ,균미출현전절종합정 ,무수혈、사망병례.결론 국산120 W고공솔록격광치료BPH시수술안전 ,병발증소 ,능체도만의적료효.
Objective To evaluate the therapeutic efficacy of made-in-China 120 W green laser photoselective vaporiza-tion of the prostate (PVP) in the treatment of benign prostatic hyperplasia .Methods From Feb .2013 to Dec .2013 ,150 pa-tients received PVP procedures in our department . Pre-operative , peri-operative and post-operative data , including Qmax , post-void residual and IPSS were recorded and analyzed .Results Of all patients ,136 were treated with PVP ,and 14 were first treated with PVP and then converted to TURP .The averaged operation time was (38 ± 20 .5)min ,serum sodium before and after operation were (139 ± 1 .0)mmol/L and (138 .5 ± 1 .9)mmol/L ,respectively .The mean laser energy used was (216 ± 58)kJ ,and catheterization time was (40 ± 18)h .No serious complications occurred during the follow-up of 3 months .The Qmax ,PVR and IPSS were significantly improved after operation .Conclusion The made-in-China 120 W green laser PVP is safe and effective for the treatment of benign prostatic hyperplasia .